Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.79 |
| ▸ | MGLL | Q99685 | 13/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | UBE2M | P61081 | 1/20 | 0.59 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1534281 | 0.89 | MAPT (1.00) | MAPTMGLLEPHX2MEN1KMT2A | |
| SCHEMBL7303372 | 0.82 | ALOX5 (0.68) | MAPTEPHX2KMT2A | |
| SCHEMBL23086080 | 0.81 | MGLL (1.00) | MAPTMGLLMEN1KMT2AUBE2M | |
| SCHEMBL3937303 | 0.80 | EPHX2 (0.77) | MAPTEPHX2 | |
| SCHEMBL3945175 | 0.79 | EPHX2 (1.00) | MAPTMGLLEPHX2 | |
| SCHEMBL3937940 | 0.78 | EPHX2 (0.72) | EPHX2 | |
| SCHEMBL29067098 | 0.76 | ACHE (0.58) | MAPTMGLLKMT2A | |
| SCHEMBL29978796 | 0.76 | EPHX2 (0.78) | EPHX2 | |
| SCHEMBL6208966 | 0.75 | MGLL (1.00) | MAPTMGLLMEN1KMT2AHSD11B1 | |
| SCHEMBL1720910 | 0.75 | MGLL (1.00) | MAPTMGLLMEN1KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046329-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2008016884-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-02-07 | — | — | WO | claimed |
| EP-2046329-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008016884-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016884-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | MAPT 3875/4885MGLL 181/4885EPHX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.